TABLES S2 Rating of individual items of the Risk of Bias tool for each study

## **Note: CSR: Clinical Study Report**

### Avendano Sola C et al [17]

ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/parsonnal	UNCLEAR	Not specified.
Blinding assessor	UNCLEAR	Not specified.
Incomplete data outcome	LOW	outcomes relevant for the present meta-analysis mentioned in the full CSK were reported in the Journal
Selective reporting	UNCLEAR	Not specified.
Other bias	LOW	All reported in published papers.
Notes	First author	unable to provide additional details.

# Cao B et al [18]

ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Billiaing	<b>UNCLEAR</b>	Not specified.
Blinding assessor	UNCLEAR	Not specified.
Incomplete data outcome	LOW	outcomes relevant for the present meta-analysis mentioned in the full CSK were reported in the Journal
Selective reporting	UNCLEAR	Not specified.
Other bias	UNCLEAR	No details on other bias.
Notes	First author	unable to provide additional details.

## Davoudi-Monfared E et al [19]

- m · v · · · · · · · · · · · · · · · · ·		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	UNCLEAR	No protocol/CSR available.
Blinding assessor	UNCLEAR	No protocol/CSR available.
Incomplete data outcome	LOW	outcomes relevant for the present meta-analysis mentioned in the full CSK were reported in the Journal
Selective reporting	UNCLEAR	No details on selective reporting.
Other bias	UNCLEAR	No details on other bias.

First author contacted but not able to provide additional information.
--

### Edalatifard M et al [20]

ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from journal article, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	UNCLEAR	No protocol/CSR available.
Blinding assessor	UNCLEAR	No protocol/CSR available.
Incomplete data outcome	UNCLEAR	No protocol/CSR available.
Selective reporting	UNCLEAR	No protocol/CSR available.
Other bias	LOW	All outcomes of relevance reported in published journal article.
Notes	First author	unable to provide additional details.

### Furtado RHM et al [21]

ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	orticle
Selective reporting	UNCLEAR	No protocol/CSR available.
Other bias	LOW	All outcomes of relevance reported in published journal article.

# Lescure FX et al [22]

ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal
Selective reporting	LOW	All officemes listed in crimialtrial gov were reported in the journal article (which included additional

Other bias	UNCLEAR Not specified.
Notes	Authors not able to provide additional information.

# Li L et al [23]

ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
	LOW	Information from the Journal article, Method of Assigning Subjects to Treatment Groups.
Binding participants/parsonnal	UNCLEAR	No protocol/CSR available.
Blinding assessor	UNCLEAR	No protocol/CSR available.
Incomplete data outcome	LOW	Outcomes relevant for the present meta-analysis mentioned were reported in the Journal article.
Selective reporting	UNCLEAR	No protocol/CSR available.
Other bias	LOW	All reported in published papers.
Notes	First author	contacted but not able to provide additional information.

# Miller J et al [24]

ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
	LOW	Information from full article, Method of Assigning Subjects to Treatment Groups.
Billiaing participants/parsonnal	<b>UNCLEAR</b>	No protocol/CSR available.
Blinding assessor	<b>UNCLEAR</b>	No protocol/CSR available.
Incomplete data outcome	<b>UNCLEAR</b>	No protocol/CSR available.
Selective reporting	UNCLEAR	No protocol/CSR available.
Other bias	HIGH	No information on how other bias was preserved.
Notes	Correspond	ing author not able to provide additional details.

### Olender SA et al [25]

ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/parsonnal	UNCLEAR	Not specified.
Blinding assessor	UNCLEAR	Not specified.
Incomplete data outcome	LOW	outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal
Selective reporting	LOW	Outcomes listed in short CSR reported in the journal article.
Other bias	UNCLEAR	Not specified.

Notes	Authors not able to provide additional information.
-------	---

### Rahmani H et al [26]

ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Billiaing	<b>UNCLEAR</b>	Not specified.
Blinding assessor	UNCLEAR	Not specified.
Incomplete data outcome	LOW	outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal
Selective reporting	UNCLEAR	Not specified.
Other bias	UNCLEAR	Not specified.
Notes	First author contacted but not able to provide additional information.	

### Rasheed AM et al [27]

ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/parsonnal	UNCLEAR	Not specified.
Blinding assessor	UNCLEAR	Not specified.
Incomplete data outcome	LOW	outcomes relevant for the present meta-analysis mentioned in the full CSK were reported in the Journal
Selective reporting	UNCLEAR	Not specified.
Other bias	HIGH	No information on how other bias was preserved.
Notes	First author	unable to provide additional details.

#### Simonovich VA et al [28]

Simonovicii vii et ai [20]		
ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal
Selective reporting	LOW	Outcomes listed in short CSR reported in the journal article.
Other bias	UNCLEAR	Not specified.

Notes	First author contacted but not able to provide additional information.
-------	--

## Veiga VC et al [29]

ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Incomplete data outcome	LOW	outcomes relevant for the present meta-analysis mentioned in the full CSR were reported in the Journal
Selective reporting	UNCLEAR	Not specified.
Other bias	UNCLEAR	Not specified.
Notes	First author	contacted but not able to provide additional information.

### Zhong M et al [30]

ITEM	RATING	SUPPORT
Random sequence generation	LOW	Received medications and placebo in a random order, double-blind.
Allocation concealment	LOW	Information from full CSR, Method of Assigning Subjects to Treatment Groups.
Blinding participants/personnel	LOW	"Investigator and the patient were blinded to treatment. To maintain blinding, all investigational products were supplied." Information from full CSR, Blinding.
Blinding assessor	UNCLEAR	Not specified.
Incomplete data outcome	UNCLEAR	Not specified.
Selective reporting	UNCLEAR	Not specified.
Other bias	HIGH	No information on how other bias was preserved.
Notes	Authors not	able to provide additional information.